當(dāng)前位置：首頁(yè) JCRQ2 期刊介紹(非官網(wǎng))

Immunopharmacology And ImmunotoxicologySCIE

國(guó)際簡(jiǎn)稱：IMMUNOPHARM IMMUNOT 參考譯名：免疫藥理學(xué)和免疫毒理學(xué)

中科院分區(qū)
4區(qū)
CiteScore分區(qū)
Q2
JCR分區(qū)
Q2

基本信息：: ISSN：0892-3973; E-ISSN：1532-2513; 是否OA：未開放; 是否預(yù)警：否; TOP期刊：否

出版信息：: 出版地區(qū)：UNITED STATES; 出版商：Informa Healthcare; 出版語(yǔ)言：English; 出版周期：Quarterly; 出版年份：1987; 研究方向：醫(yī)學(xué)-毒理學(xué)

評(píng)價(jià)信息：: 影響因子：2.9; H-index：42; CiteScore指數(shù)：5.4; SJR指數(shù)：0.68; SNIP指數(shù)：0.679

發(fā)文數(shù)據(jù)：: Gold OA文章占比：4.26%; 研究類文章占比：86.44%; 年發(fā)文量：59; 自引率：0; 開源占比：0.0297; 出版撤稿占比：0.0136...; 出版國(guó)人文章占比：0.35; OA被引用占比：0

投稿咨詢加急見刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問(wèn)題

英文簡(jiǎn)介Immunopharmacology And Immunotoxicology期刊介紹

The journal Immunopharmacology and Immunotoxicology is devoted to pre-clinical and clinical drug discovery and development targeting the immune system. Research related to the immunoregulatory effects of various compounds, including small-molecule drugs and biologics, on immunocompetent cells and immune responses, as well as the immunotoxicity exerted by xenobiotics and drugs. Only research that describe the mechanisms of specific compounds (not extracts) is of interest to the journal.

The journal will prioritise preclinical and clinical studies on immunotherapy of disorders such as chronic inflammation, allergy, autoimmunity, cancer etc. The effects of small-drugs, vaccines and biologics against central immunological targets as well as cell-based therapy, including dendritic cell therapy, T cell adoptive transfer and stem cell therapy, are topics of particular interest. Publications pointing towards potential new drug targets within the immune system or novel technology for immunopharmacological drug development are also welcome.

With an immunoscience focus on drug development, immunotherapy and toxicology, the journal will cover areas such as infection, allergy, inflammation, tumor immunology, degenerative disorders, immunodeficiencies, neurology, atherosclerosis and more.

Immunopharmacology and Immunotoxicology will accept original manuscripts, brief communications, commentaries, mini-reviews, reviews, clinical trials and clinical cases, on the condition that the results reported are based on original, clinical, or basic research that has not been published elsewhere in any journal in any language (except in abstract form relating to paper communicated to scientific meetings and symposiums).

期刊簡(jiǎn)介Immunopharmacology And Immunotoxicology期刊介紹

《Immunopharmacology And Immunotoxicology》自1987出版以來(lái)，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙?lái)某個(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：偏慢,4-8周
醫(yī)學(xué)
TOXICOLOGY
SCIE
中科院4區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Immunopharmacology And Immunotoxicology Cite Score數(shù)據(jù)

CiteScore：5.4
SJR：0.68
SNIP：0.679

學(xué)科類別	分區(qū)	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Toxicology	Q2	58 / 133	56%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmacology	Q2	141 / 313	55%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Immunology and Allergy	Q2	115 / 233	50%
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Immunology	Q3	133 / 236	43%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫(kù)中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過(guò)影響因子(IF)這一單一指標(biāo)來(lái)評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Immunopharmacology And Immunotoxicology 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：否 Top期刊：否

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	4區(qū)	TOXICOLOGY 毒理學(xué) IMMUNOLOGY 免疫學(xué) PHARMACOLOGY & PHARMACY 藥學(xué)	3區(qū) 4區(qū) 4區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Immunopharmacology And Immunotoxicology JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：IMMUNOLOGY	SCIE	Q3	108 / 181	40.6%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q2	147 / 354	58.6%
學(xué)科：TOXICOLOGY	SCIE	Q2	49 / 106	54.2%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：IMMUNOLOGY	SCIE	Q2	85 / 181	53.31%
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q2	162 / 354	54.38%
學(xué)科：TOXICOLOGY	SCIE	Q2	53 / 106	50.47%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問(wèn)題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
CHINA MAINLAND87
Iran39
India20
South Korea13
USA12
Brazil10
Turkey9
Egypt8
Japan7
Taiwan5

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Xanthones from securidaca inappendiculata antagonizes the anti-rheumatic effect of methotrexate by inhibiting reduced folate carrier 1
Author: Zhang, Sa-sa; Wu, Yi-jin; Pan, Shu; Wang, Qi-hai; Chen, Wen-gang; Wang, Zhong-fang; Xu, Jin-ying; Zuo, Jian; Yin, Qin

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 1, pp. 16-25. DOI: 10.1080/08923973.2022.2103707
2、A comparison of panitumumab and cetuximab in the treatment of KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis
Author: Liu, Tong; Jiang, Shuai; Teng, Xue; Zhong, Lu; Liu, Mengmeng; Jin, Yao; Dong, Mei

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 1, pp. 1-9. DOI: 10.1080/08923973.2022.2112222
3、Corynoline ameliorates dextran sulfate sodium-induced colitis in mice by modulating Nrf2/NF-kappa B pathway
Author: Zhang, Haihua; Lang, Wuying; Li, Sufen; Xu, Chao; Wang, Xiumin; Li, Yunyu; Zhang, Zhiqiang; Wu, Tonglei; Feng, Minshan

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 1, pp. 26-34. DOI: 10.1080/08923973.2022.2112218
4、Sulforaphane suppresses skin squamous cell carcinoma cells proliferation through miR-199a-5p/Sirt1/CD44ICD signaling pathway
Author: Zhang, Yang; Ai, Ping; Chen, Shang-zhou; Lei, Shu-ying

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 1, pp. 52-60. DOI: 10.1080/08923973.2022.2112221
5、Monensin synergizes with chemotherapy in uveal melanoma through suppressing RhoA
Author: Zeng, Chaoxia; Long, Mingxia; Lu, Ying

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 1, pp. 35-42. DOI: 10.1080/08923973.2022.2112219
6、alpha-Cyperone ameliorates depression in mammary gland hyperplasia and chronic unpredictable mild stress rat by regulating hormone, inflammation, and oxidative stress
Author: Qiao, Nan; Wang, Qinnan; Tao, Ye; Wu, Jinna; Fang, Yong; Ni, Yusheng; Ding, Xiaowen

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 1, pp. 73-82. DOI: 10.1080/08923973.2022.2115925
7、Protective effects of Tripterygium glycoside on IL-1 beta-induced inflammation and apoptosis of rat chondrocytes via microRNA-216a-5p/TLR4/NF-kappa B axis
Author: Huang, Zhen; Song, Shuanglin; Zhang, Di; Bian, Zhenyu; Han, Jinsheng

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 1, pp. 61-72. DOI: 10.1080/08923973.2022.2115924
8、Sestrin2 suppresses ferroptosis to alleviate septic intestinal inflammation and barrier dysfunction
Author: Liu, Wei; Xu, Chanchan; Zou, Zhiqiang; Weng, Qinyong; Xiao, Ying

Journal: IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY. 2023; Vol. 45, Issue 2, pp. 123-132. DOI: 10.1080/08923973.2022.2121927